|
1
|
Gong FF, Cascino GJ, Murtagh G and Akhter
N: Circulating biomarkers for cardiotoxicity risk prediction. Curr
Treat Options Oncol. 22(46)2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Pavo N, Raderer M, Hülsmann M, Neuhold S,
Adlbrecht C, Strunk G, Goliasch G, Gisslinger H, Steger GG, Hejna
M, et al: Cardiovascular biomarkers in patients with cancer and
their association with all-cause mortality. Heart. 101:1874–1880.
2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Stein GY, Alon D, Korenfeld R and Fuchs S:
Clinical implications of high-sensitivity cardiac troponin
measurements in hospitalized medical patients. PLoS One.
10(e0117162)2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Lyngbakken MN, Aagaard EN, Kvisvik B,
Berge T, Pervez MO, Brynildsen J, Tveit A, Steine K, Røsjø H and
Omland T: Cardiac troponin I and T are associated with left
ventricular function and structure: Data from the akershus cardiac
examination 1950 study. Clin Chem. 66:567–578. 2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Normann J, Mueller M, Biener M, Vafaie M,
Katus HA and Giannitsis E: Effect of older age on diagnostic and
prognostic performance of high-sensitivity troponin T in patients
presenting to an emergency department. Am Heart J. 164:698–705.e4.
2012.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Masson S, Latini R, Mureddu GF, Agabiti N,
Miceli M, Cesaroni G, Forastiere F, Wienhues-Thelen UH, Block D,
Zaugg C, et al: High-sensitivity cardiac troponin T for detection
of subtle abnormalities of cardiac phenotype in a general
population of elderly individuals. J Intern Med. 273:306–317.
2013.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Bernstein LH, Zions MY, Alam ME, Haq SA,
Heitner JF, Zarich S, Seamonds B and Berger S: What is the best
approximation of reference normal for NT-proBNP? Clinical levels
for enhanced assessment of NT-proBNP (CLEAN). J Med Lab Diag.
2:16–21. 2011.
|
|
8
|
Burjonroppa SC, Tong AT, Xiao LC, Johnson
MM, Wamique YS and Lenihan DJ: Cancer patients with markedly
elevated B-type natriuretic peptide may not have volume overload.
Am J Clin Oncol. 30:287–293. 2007.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Popat J, Rivero A, Pratap P and Guglin M:
What is causing extremely elevated amino terminal brain natriuretic
peptide in cancer patients? Congest Heart Fail. 19:143–148.
2013.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Cardinale D, Sandri MT, Colombo A, Colombo
N, Boeri M, Lamantia G, Civelli M, Peccatori F, Martinelli G,
Fiorentini C and Cipolla CM: Prognostic value of troponin I in
cardiac risk stratification of cancer patients undergoing high-dose
chemotherapy. Circulation. 109:2749–2754. 2004.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Danese E, Montagnana M, Giudici S, Aloe R,
Franchi M, Guidi GC and Lippi G: Highly-sensitive troponin I is
increased in patients with gynecological cancers. Clin Biochem.
46:1135–1138. 2013.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Blaes AH, Rehman A, Vock DM, Luo X, Menge
M, Yee D, Missov E and Duprez D: Utility of high-sensitivity
cardiac troponin T in patients receiving anthracycline
chemotherapy. Vasc Health Risk Manag. 11:591–594. 2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Lim E, Li Choy L, Flaks L, Mussa S, Van
Tornout F, Van Leuven M and Parry GW: Detected troponin elevation
is associated with high early mortality after lung resection for
cancer. J Cardiothorac Surg. 1(37)2006.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Narayan V, Thompson EW, Demissei B, Ho JE,
Januzzi JL Jr and Ky B: Mechanistic Biomarkers Informative of Both
Cancer and Cardiovascular Disease: JACC State-of-the-art review. J
Am Coll Cardiol. 75:2726–2737. 2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Narayan V and Ky B: Common cardiovascular
complications of cancer therapy: Epidemiology, risk prediction, and
prevention. Ann Rev Med. 69:97–111. 2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Lyon AR, Dent S, Stanway S, Earl H,
Brezden-Masley C, Cohen-Solal A, Tocchetti CG, Moslehi JJ, Groarke
JD, Bergler-Klein J, et al: Baseline cardiovascular risk assessment
in cancer patients scheduled to receive cardiotoxic cancer
therapies: A position statement and new risk assessment tools from
the cardio-oncology study group of the heart failure association of
the European society of cardiology in collaboration with the
international cardio-oncology society. Eur J Heart Fail.
22:1945–1960. 2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Van Cutsem E, Cervantes A, Adam R, Sobrero
A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson
A, Bodoky G, et al: ESMO consensus guidelines for the management of
patients with metastatic colorectal cancer. Ann Oncol.
27:1386–1422. 2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Alberti KG, Eckel RH, Grundy SM, Zimmet
PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith
SC Jr, et al: Harmonizing the metabolic syndrome: A joint interim
statement of the international diabetes federation task force on
epidemiology and prevention; national heart, lung, and blood
institute; American heart association; world heart federation;
international atherosclerosis society; and international
association for the study of obesity. Circulation. 120:1640–1645.
2009.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Arora G, Morss AM, Piazza G, Ryan JW,
Dinwoodey DL, Rofsky NM, Manning WJ and Chuang ML: Differences in
left ventricular ejection fraction using teichholz formula and
volumetric methods by cmr: Implications for patient stratification
and selection of therapy. J Cardiovasc Magn Reson.
12(P202)2010.
|
|
20
|
Demissei BG, Hubbard RA, Zhang L, Smith
AM, Sheline K, McDonald C, Narayan V, Domchek SM, DeMichele A, Shah
P, et al: Changes in cardiovascular biomarkers with breast cancer
therapy and associations with cardiac dysfunction. J Am Heart
Assoc. 9(e014708)2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Kang Y, Xu X, Cheng L, Li L, Sun M, Chen
H, Pan C and Shu X: Two-dimensional speckle tracking
echocardiography combined with high-sensitive cardiac troponin T in
early detection and prediction of cardiotoxicity during
epirubicine-based chemotherapy. Eur J Heart Fail. 16:300–308.
2014.PubMed/NCBI View
Article : Google Scholar
|
|
22
|
Daher IN, Kim C, Saleh RR, Plana JC, Yusuf
SW and Banchs J: Prevalence of abnormal echocardiographic findings
in cancer patients: A retrospective evaluation of echocardiography
for identifying cardiac abnormalities in cancer patients.
Echocardiography. 28:1061–1067. 2011.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Patel DA, Lavie CJ, Milani RV, Shah S and
Gilliland Y: Clinical implications of left atrial enlargement: A
review. Ochsner J. 9:191–196. 2009.PubMed/NCBI
|
|
24
|
Yeboah J, Bluemke DA, Hundley WG,
Rodriguez CJ, Lima JA and Herrington DM: Left ventricular dilation
and incident congestive heart failure in asymptomatic adults
without cardiovascular disease: Multi-ethnic study of
atherosclerosis (MESA). J Card Fail. 20:905–911. 2014.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Milwidsky A, Fisher E, Brzezinski RY,
Ehrenwald M, Shefer G, Stern N, Shapira I, Zeltser D, Rosenbaum Z,
Greidinger D, et al: Metabolic syndrome is associated to
high-sensitivity cardiac troponin T elevation. Biomarkers.
24:153–158. 2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Hickman PE, Abhayaratna WP, Potter JM and
Koerbin G: Age-related differences in hs-cTnI concentration in
healthy adults. Clin Biochem. 69:26–29. 2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Gore MO, Seliger SL, Defilippi CR, Nambi
V, Christenson RH, Hashim IA, Hoogeveen RC, Ayers CR, Sun W,
McGuire DK, et al: Age- and sex-dependent upper reference limits
for the high-sensitivity cardiac troponin T assay. J Am Coll
Cardiol. 63:1441–1448. 2014.PubMed/NCBI View Article : Google Scholar
|
